EU approves daraxonrasib as first targeted pill for advanced pancreatic cancer

The European Commission has approved daraxonrasib, a daily pill targeting KRAS mutations, for advanced pancreatic cancer. While early trials show tumours shrinking or vanishing in some patients, experts warn it is not a cure and longer studies are needed to confirm survival benefits.
Key points
- The European Commission approved daraxonrasib, branded as Rasonque, for adult patients with advanced pancreatic cancer who have previously received at least one cancer treatment.
- The drug targets RAS mutations, which drive tumour growth in approximately 90% of pancreatic cancer cases, by shutting down specific cellular proteins.
- In a study of 500 patients, those taking daraxonrasib survived an average of 12.4 months, compared to 6.7 months for those receiving standard chemotherapy.
- Early trials involving 61 participants showed that 90% experienced halted tumour growth, while 8% saw their tumours become undetectable on scans.
- The European Medicines Agency recommended approval in October, with the final decision coming in November 2026.
Background
Recent archive coverage highlights a surge in KRAS-targeted therapies, including vaccines that trigger strong immune responses but have yet to prove significant survival benefits. While some patients have remained cancer-free for years after personalized mRNA treatments, broader regulatory challenges and funding concerns persist in the sector.
How outlets are covering it
BBC emphasizes the potential for tumours to vanish in early trials, calling it a major breakthrough, but stresses the need for longer studies to confirm remission. Yahoo focuses on the regulatory approval and survival data, noting that the drug extends life compared to chemotherapy but does not promise a cure. Both sources agree that the drug targets a mutation prevalent in most pancreatic cancers, though BBC highlights its potential application to other cancers like lung and ovarian, while Yahoo notes the disease is often detected late due to non-specific symptoms.
Why it matters
Pancreatic cancer has the lowest survival rate among common cancers in the UK, with 11,500 diagnoses and 10,200 deaths annually. This approval offers a new treatment option that may extend survival and improve quality of life for patients with advanced disease, potentially impacting other cancers with similar mutations.
What to watch
Longer clinical trials are required to determine if the drug can induce lasting remission and how long it keeps the disease at bay. Researchers are also exploring its application in other cancers with similar KRAS mutations, such as lung and ovarian cancer.
- Massive hope for pancreatic cancer pill after trial saw tumours vanish BBC
- ‘Game-changing’ pancreatic cancer drug can make tumours vanish The Times
- Spotlight On: Revolution CEO — 'One company said they watch everything we do, and try to reproduce it their own way' FirstWord Pharma
- RVMD: RASONQUE’s launch opens a broad push to establish RAS-directed treatment across cancer settings TradingView
- EU approves new drug for pancreatic cancer Yahoo
Want the full story? Read the original reporting
Read on BBC